Cargando…

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells

SIMPLE SUMMARY: Human natural killer (NK) cells can be targeted to tumor antigens by their IgG Fc receptors that interact with the Fc regions of antibodies that recognize surface proteins on cancer cells. Therapeutic antibodies specific to cancer cell antigens are used to treat various malignancies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Dixon, Kate J., Wu, Jianming, Walcheck, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829765/ https://www.ncbi.nlm.nih.gov/pubmed/33467027 http://dx.doi.org/10.3390/cancers13020312

Ejemplares similares

Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells
por: Hullsiek, Robert, et al.
Publicado: (2022)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells
por: Jing, Yawu, et al.
Publicado: (2015)

FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV
por: Talathi, Sneha Pramod, et al.
Publicado: (2019)

Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells
por: Snyder, Kristin M., et al.
Publicado: (2018)

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
por: Mohseni Nodehi, Sahar, et al.
Publicado: (2012)

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020)

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
por: Kline, James Bradford, et al.
Publicado: (2017)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
por: Lledo‐Garcia, Rocio, et al.
Publicado: (2021)

Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afucosylated IgG for enhanced ADCC
por: Mao, Changchuin, et al.
Publicado: (2021)

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors: Fc-mediated avidity enhances the potency of an anti-TLR4 antibody
por: Loyau, Jérémy, et al.
Publicado: (2014)

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy
por: Oppenheim, D E, et al.
Publicado: (2014)

High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19
por: Vietzen, Hannes, et al.
Publicado: (2022)

In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
por: Thomann, Marco, et al.
Publicado: (2015)

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
por: Nordstrom, Jeffrey L, et al.
Publicado: (2011)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
por: Gogesch, Patricia, et al.
Publicado: (2021)

NK Cell-Fc Receptors Advance Tumor Immunotherapy
por: Sanseviero, Emilio
Publicado: (2019)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Monoclonal antibodies and Fc fragments for treating solid tumors
por: Eisenbeis, Andrea M, et al.
Publicado: (2012)

Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation
por: Mishra, Hemant K., et al.
Publicado: (2021)

Fc-engineered monoclonal antibodies to reduce off-target liver uptake
por: Mangeat, Tristan, et al.
Publicado: (2023)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus
por: Vlahava, Virginia-Maria, et al.
Publicado: (2021)

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
por: Mackness, Brian C., et al.
Publicado: (2019)

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

FcγR Binding and ADCC Activity of Human IgG Allotypes
por: de Taeye, Steven W., et al.
Publicado: (2020)

The Yin and Yang of ADCC-Mediating Antibodies
por: Robert-Guroff, Marjorie
Publicado: (2016)

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity
por: Gong, Ying, et al.
Publicado: (2021)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021)

“Universal Flu Vaccine”: Can NK Cell-mediated ADCC Tip the Scales?
por: Hassane, Maya, et al.
Publicado: (2016)

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
por: Natsume, Akito, et al.
Publicado: (2009)

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
por: Mata-Molanes, Juan J., et al.
Publicado: (2022)

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
por: Valente, Delphine, et al.
Publicado: (2020)

P04-36. HIV-1-speficic antibody dependant cellular cytotoxicity (ADCC) médiated by primary NK cells
por: Delaporte, M, et al.
Publicado: (2009)

Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
por: Ramdani, Yanis, et al.
Publicado: (2022)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ejf0u61n2nlleajeaalt4ott4s